NATCO Pharma wins Risdiplam patent case, to launch generic drug immediately at ₹15,900 MRP
NATCO Pharma won a patent case against Roche, allowing immediate launch of generic Risdiplam for SMA at ₹15,900, with a patient access program to ensure affordability.
The impact is high because this legal win removes a major barrier, allowing NATCO Pharma to enter a new therapeutic area with a life-saving drug. The immediate launch and competitive pricing have significant revenue potential and positive social implications, enhancing the company's market position and reputation.
The announcement is highly positive as NATCO Pharma secured a significant legal victory, enabling the immediate launch of a critical, previously unaffordable drug (Risdiplam) in India, which is expected to address a major public health need and open a new market for the company.
* NATCO Pharma Limited announced that the Commercial Appellate Division of the Hon'ble Delhi High Court dismissed an appeal filed by F. Hoffmann-La Roche AG on October 9, 2025. * This decision removes the final hurdle for NATCO Pharma to launch a generic version of 'Risdiplam', a drug used to treat Spinal Muscular Atrophy (SMA). * A Ld. Single Judge of the Delhi High Court had previously denied Roche's injunction plea on March 24, 2025, emphasizing public interest due to the original drug's unaffordable pricing in India. * SMA is a debilitating disease, and current treatment options are often financially unfeasible for Indian patients. * NATCO Pharma will launch the product with immediate effect, pricing it at an MRP of ₹15,900 and intends to offer discounts through a patient access programme.
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under litigation updates. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.